RICCIARDI, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 237
EU - Europa 211
AS - Asia 72
SA - Sud America 3
AF - Africa 2
Totale 525
Nazione #
US - Stati Uniti d'America 229
IT - Italia 65
CN - Cina 30
FR - Francia 23
IE - Irlanda 22
SG - Singapore 21
GB - Regno Unito 19
IN - India 15
NL - Olanda 14
SE - Svezia 14
DE - Germania 10
GR - Grecia 7
BA - Bosnia-Erzegovina 6
CA - Canada 5
PL - Polonia 4
RS - Serbia 4
SI - Slovenia 4
ES - Italia 3
HR - Croazia 3
MX - Messico 3
AT - Austria 2
BR - Brasile 2
CH - Svizzera 2
DK - Danimarca 2
KR - Corea 2
ME - Montenegro 2
NG - Nigeria 2
UA - Ucraina 2
AM - Armenia 1
AR - Argentina 1
BE - Belgio 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
JP - Giappone 1
RO - Romania 1
Totale 525
Città #
Chandler 46
Santa Clara 31
Dublin 22
Singapore 17
Milan 14
Amsterdam 12
Nyköping 11
Rome 7
Banja Luka 6
London 6
Paris 6
Preveza 6
Turin 6
Ashburn 5
Chaponost 5
Columbus 5
Medford 5
Mumbai 5
Princeton 5
Belgrade 4
Brookline 4
Fairfield 4
Hangzhou 4
Jacksonville 4
Newcastle upon Tyne 4
Torino 4
Beijing 3
Chengdu 3
Chennai 3
Coyoacán 3
Genay 3
Hyderabad 3
Toulouse 3
Vancouver 3
Zagreb 3
Abuja 2
Andover 2
Atlanta 2
Bengaluru 2
Birmingham 2
Boston 2
Cambridge 2
Celje 2
Dearborn 2
Dossobuono 2
Flanders 2
Fuzhou 2
Genoa 2
Guangzhou 2
Hebei 2
Houston 2
Lake Villa 2
Lenart v Slov. Goricah 2
Madrid 2
Messina 2
Mutterstadt 2
New Delhi 2
New York 2
Nuremberg 2
Padova 2
Philadelphia 2
Phoenixville 2
Pomezia 2
San Francisco 2
Seoul 2
Sevenoaks 2
Shenzhen 2
Stockholm 2
Tarbes 2
Vejle 2
Westfield 2
Woodstock 2
Ann Arbor 1
Brooklyn 1
Brussels 1
Budapest 1
Calgary 1
Cardito 1
Changsha 1
Cluj-Napoca 1
Coventry 1
Ferrara 1
Frattamaggiore 1
Fremont 1
Geneva 1
Guiyang 1
Gunzenhausen 1
Hellikon 1
Hopkins 1
Jakarta 1
Kettering 1
Krakow 1
Kunming 1
Lancaster 1
Mannheim 1
Milanówek 1
Monmouth Junction 1
Nanjing 1
Norwalk 1
Parma 1
Totale 377
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 276
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial 84
Expected and paradoxical effects of obesity on cancer treatment response 65
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 58
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 51
Totale 534
Categoria #
all - tutte 1.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.722


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202016 0 0 0 0 0 3 6 2 1 1 3 0
2020/202126 0 1 0 0 1 0 1 1 12 4 3 3
2021/202258 3 1 2 1 4 4 5 3 2 4 19 10
2022/2023223 22 19 5 14 13 34 20 21 33 16 14 12
2023/2024134 13 32 15 9 11 15 7 12 1 11 4 4
2024/202570 1 7 5 12 34 11 0 0 0 0 0 0
Totale 534